NOTES TO CONSOLIDATED ANNUAL FINANCIAL STATEMENTS CONTINUED

for the year ended 30 September 2020

27. DIRECTORS' EMOLUMENTS AND INTERESTS IN THE COMPANY

Emoluments paid to the directors and prescribed officers of the Company by the Company and its subsidiaries for the year to 30 September, are set out below:

	2020			2019		
Executive directors – shareholding	**Direct**	**Indirect[3]**	**Associate interest**	Direct	Indirect[2]	Associate interest
Executive directors						
PG Wharton-Hood[1]	**300 000**	**862 706**	**–**	–	–	–
PP van der Westhuizen[2]	**241 636**	**350 000**	**4 832**	164 746	–	4 832
Past executive director						
SB Viranna[4]		**n/a**		170 515	224 731	–
	541 636	**1 212 706**	**4 832**	335 261	224 731	4 832

Executive directors – total remuneration earned	**Salaries R'000**	**Bonus and performance-related payments R'000**	**Performance-related accrual relating to current year R'000**
2020			
Executive directors			
PG Wharton-Hood[1]	**641**	**–**	**–**
PP van der Westhuizen	**5 333**	**1 853**	**3 394**
PP van der Westhuizen[5]	**–**	**–**	**–**
Past executive director			
SB Viranna[4]	**3 083**	**–**	**–**
	9 057	**1 853**	**3 394**
2019			
Executive directors			
SB Viranna[4]	5 887	2 624	4 462
PP van der Westhuizen	4 084	2 352	2 311
	9 971	4 976	6 773

[1] PG Wharton-Hood was appointed as Chief Executive Officer on 1 September 2020.

[2] PP van der Westhuizen purchased 58 500 shares on 20 November 2020, increasing his direct shareholding to 300 136. PP van der Westhuizen was granted 600 shares on 2 December 2020, increasing his indirect shareholding to 350 600. Refer note 19.

[3] The indirect beneficial shareholding is subject to vesting conditions. Refer note 19.

[4] SB Viranna resigned as Chief Executive Officer with effect from 17 January 2020. Leave payout amounted to R14 000.

[5] PP van der Westhuizen in his capacity as acting Chief Executive Officer from 18 January 2020 to 31 August 2020.

[6] Relates to notional shares. Shares were only purchased on vesting.

CEO acting allowance and bonus[5] R'000	Other allowances R'000	Gains on long-term incentive scheme[6] R'000	Medical aid contributions R'000	Pension fund contribution R'000	Total remuneration R'000
–	**10**	**–**	**–**	**27**	**678**
–	**146**	**776**	**6**	**226**	**11 734**
2 425	**–**	**–**	**–**	**–**	**2 425**
–	**31**	**2 805**	**5**	**129**	**6 053**
2 425	**187**	**3 581**	**11**	**382**	**21 234**
–	33	3 038	32	247	16 323
–	95	460	37	174	9 513
–	128	3 498	69	421	25 836

NOTES TO CONSOLIDATED ANNUAL FINANCIAL STATEMENTS CONTINUED

for the year ended 30 September 2020

27. DIRECTORS' EMOLUMENTS AND INTERESTS IN THE COMPANY continued

	Awards received during 2020		
Long-term incentive scheme	Number of shares	Date of issue	Issue price R/share
PG Wharton-Hood 2020 allocation[1]	**862 706**	**Sep 20**	**17.39**

	Dividends	Closing balance at 30 September 2020	
Long-term incentive scheme	Value of dividends in respect of all plans (R)	Number of shares	Final vesting date
PG Wharton-Hood 2020 allocation[1]	**–**	**862 706**	**Dec 25**

	Opening balance at 1 October 2019	Awards received during 2020		
Long-term incentive scheme	Number of shares	Number of shares	Date of issue	Issue price R/share
PP van der Westhuizen 2020 allocation[1]	–	**350 000**	**Sep 20**	**17.11**

	Dividends	Closing balance at 30 September 2020	
Long-term incentive scheme	Value of dividends in respect of all plans (R)	Number of shares	Final vesting date
PP van der Westhuizen 2020 allocation[1]	**–**	**350 000**	**Dec 25**

[1] *Refer note 19.*

27. DIRECTORS' EMOLUMENTS AND INTERESTS IN THE COMPANY continued

	Total shareholding shares		Directors' fees R'000	
	2020	2019	**2020**	2019
Non-Executive directors				
MA Brey[1]	**4 300 349**	4 900 349	**1 136**	1 175
PJ Golesworthy[2]	**31 224**	31 224	**1 061**	1 080
ME Jacobs	**–**	–	**591**	507
VL Litlhakanyane[3]	**–**	–	**221**	–
AM Mothupi	**–**	–	**667**	664
JK Netshitenzhe	**–**	–	**501**	421
MP Ngatane	**–**	–	**572**	493
M Sello	**–**	–	**397**	421
GC Solomon[2]	**143 612**	143 612	**729**	810
RT Vice	**–**	–	**712**	826
	4 475 185	5 075 185	**6 587**	6 397

[1] *MA Brey's direct beneficial shareholding is 716 370 (2019: 716 370), his indirect beneficial shareholding is 3 484 787 (2019: 4 084 787) and his associate interest is 99 192 (2019: 99 192).*
[2] *PJ Golesworthy and GC Solomon's total shareholding only includes direct beneficial shares.*
[3] *VL Litlhakanyane was appointed as non-executive director on 15 April 2020.*

The directors' fees are paid by a subsidiary company of Life Healthcare Group Holdings Limited.

Prescribed officers

In line with the requirements of the Companies Act, the Group discloses the remuneration paid to prescribed officers who are defined as the Chief Executive Officer, the Chief Financial Officer, Chief Executive Officer – southern Africa and Chief Executive Officer – International.

	Total share-holding	Salaries R'000	Bonus and per-formance-related payments R'000	Perfor-mance-related accrual relating to current year R'000	Other allow-ances R'000	Gains on long-term incentive scheme R'000	Medical aid contri-butions R'000	Pension fund contri-butions R'000	Total remun-eration R'000
2020									
PG Wharton-Hood PP van der Westhuizen	**Refer emoluments disclosed under executive directors**								
AM Pyle	**82 590**	**3 331**	**1 273**	**2 012**	**18**	**405**	**6**	**151**	**7 196**
MD Chapman	**185 787**	**5 535**	**–**	**2 854**	**259**	**–**	**–**	**569**	**9 217**
2019									
SB Viranna PP van der Westhuizen	Refer emoluments disclosed under executive directors								
AM Pyle	–	3 374	1 469	2 357	151	–	37	142	7 530
MD Chapman[4]	–	1 681	–	1 232	61	–	–	168	3 142

[4] *MD Chapman was appointed as a prescribed officer from 1 June 2019.*

Total shareholding for AM Pyle and MD Chapman is subject to vesting conditions. Refer note 19.

NOTES TO CONSOLIDATED ANNUAL FINANCIAL STATEMENTS CONTINUED

for the year ended 30 September 2020

27. DIRECTORS' EMOLUMENTS AND INTERESTS IN THE COMPANY continued

Long-term incentive scheme	Awards received during 2020	
	Number of shares	Issue price R/share
AM Pyle		
2020 allocation[1]	**82 590**	**21.97**

Long-term incentive scheme	Dividends	Closing balance at 30 September 2020	
	Value of dividends in respect of all plans (R)	Number of shares	Final vesting date
AM Pyle			
2020 allocation[1]	**n/a**	**82 590**	**31 Mar 2021**

Long-term incentive scheme	Opening balance at 1 October 2019		Awards received during 2020	
	Number of shares	Issue price R/share	Number of shares	Issue price R/share
MD Chapman				
2020 allocation[1]	–	–	**185 787**	**21.97**
C convertible shares	10 000	n/a	**–**	**–**

Long-term incentive scheme	Dividends	Closing balance at 30 September 2020	
	Value of dividends in respect of all plans (R)	Number of shares	Final vesting date
MD Chapman			
2020 allocation[1]	**n/a**	**185 787**	**30 Sep 2021**
C convertible shares	**n/a**	**10 000**	**30 Sep 2021**

[1] *Refer note 19.*

No director or prescribed officer has a notice period of more than six months. No director's service contract includes predetermined compensation as a result of termination that would exceed one year's salary and benefits.